Literature DB >> 22640435

Cutting edge in medical management of cutaneous oncology.

Kim Chong1, Adil Daud, Susana Ortiz-Urda, Sarah T Arron.   

Abstract

Traditional chemotherapy has resulted in only a modest response, if any, for the 3 most common cutaneous malignancies of basal cell carcinoma, squamous cell carcinoma, and melanoma. Recent advances in understanding of the defects in the pathways driving tumorigenesis have changed the way that we think of these cancers and paved the way to targeted therapy for specific tumors. In this review, we will introduce the novel systemic treatments currently available for these cancers in the context of what is understood about the tumor pathogenesis. We will also introduce ongoing studies that will hopefully broaden our options for highly effective and tolerable treatment.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22640435      PMCID: PMC3367308          DOI: 10.1016/j.sder.2012.03.002

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  83 in total

1.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

Authors:  R Sears; F Nuckolls; E Haura; Y Taya; K Tamai; J R Nevins
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

Review 2.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 3.  Preclinical studies with Erlotinib (Tarceva).

Authors:  Robert W Akita; Mark X Sliwkowski
Journal:  Semin Oncol       Date:  2003-06       Impact factor: 4.929

Review 4.  The Met tyrosine kinase receptor in development and cancer.

Authors:  Alessandra Gentile; Livio Trusolino; Paolo M Comoglio
Journal:  Cancer Metastasis Rev       Date:  2008-03       Impact factor: 9.264

5.  NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.

Authors:  Kristina Buac; Mai Xu; Julie Cronin; Ashani T Weeraratna; Stephen M Hewitt; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2009-07-30       Impact factor: 4.693

6.  Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome.

Authors:  H Hahn; C Wicking; P G Zaphiropoulous; M R Gailani; S Shanley; A Chidambaram; I Vorechovsky; E Holmberg; A B Unden; S Gillies; K Negus; I Smyth; C Pressman; D J Leffell; B Gerrard; A M Goldstein; M Dean; R Toftgard; G Chenevix-Trench; B Wainwright; A E Bale
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

7.  Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.

Authors:  Mario A Economou; Charlotta All-Ericsson; Vladimir Bykov; Leonard Girnita; Armando Bartolazzi; Olle Larsson; Stefan Seregard
Journal:  Acta Ophthalmol       Date:  2008-11       Impact factor: 3.761

8.  Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.

Authors:  D M Mahvi; M B Henry; M R Albertini; S Weber; K Meredith; H Schalch; A Rakhmilevich; J Hank; P Sondel
Journal:  Cancer Gene Ther       Date:  2007-06-08       Impact factor: 5.987

9.  Treatment of cutaneous melanoma: current approaches and future prospects.

Authors:  Alain P Algazi; Christopher W Soon; Adil I Daud
Journal:  Cancer Manag Res       Date:  2010-08-17       Impact factor: 3.989

10.  Lack of clinical efficacy of imatinib in metastatic melanoma.

Authors:  S Ugurel; R Hildenbrand; A Zimpfer; P La Rosée; P Paschka; A Sucker; P Keikavoussi; J C Becker; W Rittgen; A Hochhaus; D Schadendorf
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

View more
  5 in total

1.  Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.

Authors:  Q Jiao; C Liu; W Li; W Li; F Fang; Q Qian; X Zhang
Journal:  Clin Exp Immunol       Date:  2017-03-12       Impact factor: 4.330

Review 2.  Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma.

Authors:  Philip Eliades; Keith T Flaherty; Hensin Tsao
Journal:  Melanoma Manag       Date:  2015-05-18

3.  FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms.

Authors:  Xiaoling Zhang; Joseph Wu; Suju Luo; Terry Lechler; Jennifer Y Zhang
Journal:  Oncotarget       Date:  2016-06-07

Review 4.  The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin.

Authors:  Emanuel Rognoni; Gernot Walko
Journal:  Cells       Date:  2019-05-03       Impact factor: 6.600

Review 5.  Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.

Authors:  Jean Christopher Chamcheu; Tithi Roy; Mohammad Burhan Uddin; Sergette Banang-Mbeumi; Roxane-Cherille N Chamcheu; Anthony L Walker; Yong-Yu Liu; Shile Huang
Journal:  Cells       Date:  2019-07-31       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.